Ajanta Pharma Limited (AJANTPHARM) AI Stock Analysis

• Market Cap: ₹378.42B
• Dividend Yield: 1.04%
• Average Volume (3M): 2.10K
• Price to Earnings (P/E): 31.6
• Beta (1Y): 0.43
• Revenue Growth: 10.74%
• EPS Growth: 11.91%
• Country: IN
• Employees: 8,073
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 21.91
• Shares Outstanding: 124,935,620
• 10 Day Avg. Volume: 2,991
• 30 Day Avg. Volume: 2,099
• PEG Ratio: 2.64
• Price to Book (P/B): 8.64
• Price to Sales (P/S): 7.05
• P/FCF Ratio: 39.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹3,207.50
• Price Target Upside: 9.81% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 88.06
• Revenue Forecast (FY): ₹53.79B

• Rating: 72 Outperform
• Price Target: ₹3,362.00 ▲(15.10% Upside)
• Action: Reiterated Date: 08/22/25
• Date: Action: Reiterated 08/22/25

Ajanta Pharma Limited's overall stock score is driven by its strong financial performance, which indicates robust growth and stability. The technical analysis suggests a neutral to slightly bearish short-term trend, while the valuation indicates a high P/E ratio, balanced by a moderate dividend yield. The absence of earnings call data and corporate events does not impact the score.

Positive Factors

Consistent revenue growth

Multi-year revenue expansion reflects successful execution of Ajanta's branded generics strategy across domestic and international markets. Durable top-line growth supports reinvestment into product launches, scale economies, and continued commercial expansion, underpinning sustainable earnings potential over the next 2–6 months.

Strong cash flow generation

Healthy free cash flow and strong operating cash conversion provide durable funding for capex, in-house manufacturing, regulatory filings and shareholder returns. Reliable cash generation reduces refinancing risk and supports strategic investments needed for medium-term product registrations and market expansion.

Low leverage, robust balance sheet

Low leverage and a strong equity base give Ajanta financial flexibility to pursue M&A, fund R&D, and absorb regulatory or market setbacks. Improved ROE and steady asset growth indicate efficient capital use and resilience, supporting durable competitiveness and strategic optionality over coming quarters.

Negative Factors

Geographic and regulatory complexity

Wide geographic footprint across emerging and regulated markets creates durable execution risks: staggered regulatory approvals, varied reimbursement regimes, and dependence on local distributors. These factors can elongate commercialization timelines and introduce cadence variability in revenue and margin realization over months.

Limited earnings-call disclosure

Absence of earnings-call guidance and limited public forward disclosure reduces visibility into near-term product launches, regulatory timelines, and management priorities. This information gap can increase uncertainty for investors and hinder clear assessment of execution risks and growth drivers over a 2–6 month horizon.

Thin trading liquidity

Relatively low average trading volume signals limited liquidity, which can deter large institutional participation, widen execution spreads and impede efficient price discovery. For sizable transactions or capital raises, thin liquidity is a durable constraint that can increase transaction costs and market impact risk.

Ajanta Pharma Limited Business Overview & Revenue Model

Company Description

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages. The company markets and serves various therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, cardiology, gynecology, pediatric, respiratory and general health products, dermatology, ophthalmology, and pain management areas. It also provides multivitamins, antibiotics, eye drops, cough syrups, etc. The company serves in India, Africa, rest of Asia, the United States, and internationally. It supplies its products to government bodies, including armed forces, government hospitals, canteens, stores department, etc. The company was founded in 1973 and is headquartered in Mumbai, India.

How the Company Makes Money

Ajanta Pharma primarily makes money by selling pharmaceutical formulations (finished dosage medicines) under its own brands and through its commercial presence in domestic and overseas markets. Its revenue model is centered on (1) domestic branded generics, where it promotes prescription medicines to healthcare professionals and distributes them via wholesalers/stockists and pharmacies; and (2) international sales, where it markets branded generics in selected emerging markets through its own teams and/or local distributors and sells products in regulated markets via registrations and commercial partners. Earnings are supported by in-house manufacturing (capturing manufacturing margin in addition to marketing margin), product mix management (higher-value therapies and differentiated formulations can improve realizations), and the ability to expand through new product launches and geographic expansion driven by regulatory approvals and market access. Specific material partnerships, customer concentration, or segment-wise revenue split: null.

Ajanta Pharma Limited Financial Statement Overview

Summary

Ajanta Pharma Limited exhibits strong financial health with robust revenue and profit growth, solid balance sheet stability, and effective cash flow management. The company is well-positioned to capitalize on market opportunities and sustain its competitive advantage in the pharmaceutical industry. Risks appear well-managed with low leverage and efficient operations.

Income Statement

Ajanta Pharma Limited has demonstrated strong revenue growth over the past years, with a consistent increase in total revenue from 2020 to 2025. The gross profit margin has remained robust, reflecting effective cost management and product pricing strategies. Net profit margins have improved, indicating enhanced profitability. The EBIT and EBITDA margins are healthy, suggesting operational efficiency and the ability to generate earnings from core business activities.

Balance Sheet

The company's balance sheet shows a solid equity position with a low debt-to-equity ratio, indicating financial stability and low leverage risk. The equity ratio is high, showcasing a strong reliance on equity financing. Return on equity has improved, reflecting efficient use of shareholder funds to generate profits. The company's assets have grown steadily, supporting business expansion.

Cash Flow

Ajanta Pharma Limited has shown strong cash flow generation with positive free cash flow growth, supporting reinvestment and shareholder returns. The operating cash flow to net income ratio is favorable, indicating effective conversion of net income into cash. The free cash flow to net income ratio is also healthy, reflecting good cash flow management and financial health.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	49.73B	46.48B	42.09B	37.43B	32.84B	28.47B
Gross Profit	34.79B	35.77B	30.93B	26.32B	23.97B	21.65B
EBITDA	14.04B	12.68B	12.57B	8.81B	10.44B	10.24B
Net Income	9.74B	9.20B	8.16B	5.88B	7.13B	6.54B
Balance Sheet
Total Assets	56.72B	50.15B	46.38B	46.79B	40.56B	37.79B
Cash, Cash Equivalents and Short-Term Investments	9.40B	6.15B	4.60B	8.44B	3.28B	3.78B
Total Debt	2.46B	474.20M	352.80M	356.30M	250.30M	313.60M
Total Liabilities	13.57B	12.25B	10.71B	12.91B	7.91B	7.83B
Stockholders Equity	43.15B	37.90B	35.67B	33.88B	32.64B	29.96B
Cash Flow
Free Cash Flow	1.10B	8.39B	6.33B	6.17B	4.13B	4.05B
Operating Cash Flow	2.84B	11.57B	7.85B	7.92B	5.62B	5.76B
Investing Cash Flow	-5.49B	-3.77B	653.90M	-5.60B	-741.00M	-2.82B
Financing Cash Flow	1.82B	-7.33B	-10.51B	-1.08B	-4.60B	-3.18B

Ajanta Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2920.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AJANTPHARM, the sentiment is Positive. The current price of 2920.85 is below the 20-day moving average (MA) of 2978.77, above the 50-day MA of 2867.85, and above the 200-day MA of 2635.71, indicating a bullish trend. The MACD of 52.76 indicates Negative momentum. The RSI at 57.48 is Neutral, neither overbought nor oversold. The STOCH value of 82.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:AJANTPHARM.

Ajanta Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IPCALAB	74 Outperform	₹395.91B	27.58	―	0.28%	9.66%	25.79%
AJANTPHARM	72 Outperform	₹378.42B	31.59	―	1.04%	10.74%	11.91%
JBCHEPHARM	66 Neutral	₹340.67B	36.01	―	0.86%	10.25%	17.01%
LAURUSLABS	66 Neutral	₹541.83B	59.42	―	0.15%	25.83%	421.20%
GLAND	63 Neutral	₹268.18B	27.13	―	1.07%	-1.51%	14.27%
GLENMARK	53 Neutral	₹612.38B	35.61	―	0.24%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Ajanta Pharma Limited Corporate Events

Ajanta Pharma Denies Involvement in Rumoured Restaurant Brands Asia Acquisition

Ajanta Pharma has issued a formal clarification denying media reports that it plans to raise Rs 2,000 crore to acquire Restaurant Brands Asia and diversify into the quick-service restaurant sector. The company stated that the reference to Ajanta Pharma in a recent Economic Times article is factually incorrect and that neither the company nor its management is involved in any such transaction.

According to the clarification, a section of the promoter group that manages and controls Lenexis Foodworks Pvt. Ltd. is independently pursuing the acquisition of Restaurant Brands Asia, in a transaction separate from Ajanta Pharma. By distancing itself from the reported deal, Ajanta Pharma aims to quell market rumours, prevent investor misperception about its strategic direction, and reaffirm that its core operations remain focused on pharmaceuticals rather than diversification into food services.

Ajanta Pharma Publishes Q3 and Nine-Month FY26 Results in Newspapers in Line with SEBI Norms

Ajanta Pharma Limited has notified the stock exchanges that it has published its unaudited financial results for the quarter and nine months ended 31 December 2025 in the Mumbai editions of Business Standard and Navakal, in compliance with Regulation 47 of SEBI’s Listing Obligations and Disclosure Requirements. The disclosure underscores the company’s adherence to statutory reporting norms for listed entities, ensuring continued transparency for investors and other stakeholders regarding its recent financial performance.

Ajanta Pharma to Engage Investors at Multiple February 2026 Conferences

Ajanta Pharma has announced its participation in multiple investor and analyst conferences in February 2026, including Axis Capital’s Flagship India Conference at Trident, BKC, and the Nuvama India Conference 2026 and Kotak Flagship Conference 2026, both at the Grand Hyatt in Santacruz, Mumbai. The meetings, which will include group and one-on-one interactions with analysts and institutional investors, are intended to enhance engagement with the financial community and will be limited to discussions based on information already in the public domain, underscoring the company’s adherence to disclosure regulations and its efforts to maintain transparency with stakeholders.